Who Paid My Doc
Stanley Chetcuti
Cardiovascular Disease Ann Arbor, MI Medical Doctor
NPI 1467503516 CMS profile 20638
1500 E Medical Center Dr, 3Rd Floor Cardiovascular Center, Ann Arbor, MI 48109
General payments
$572,715
Research payments
$64,850
Ownership & investment interest
$0
Research they led as principal investigator
$3,748,788
Through program year 2025, Stanley Chetcuti of Ann Arbor, MI is reported in the CMS Open Payments database as having received $572,715 across 1,462 general payments and $64,850 in research payments paid to them. Separately, studies naming them as principal investigator received $3,748,788 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $155,691 | 267 | |
| 2024 | General | $71,721 | 249 | |
| 2024 | Research | $25,850 | 6 | |
| 2023 | General | $108,218 | 263 | |
| 2023 | Research | $7,563 | 6 | |
| 2022 | General | $52,803 | 230 | |
| 2022 | Research | $16,675 | 10 | |
| 2021 | General | $63,298 | 180 | |
| 2021 | Research | $10,356 | 10 | |
| 2020 | General | $74,934 | 129 | |
| 2020 | Research | $4,406 | 9 | |
| 2019 | General | $46,050 | 144 |
Beside peers
- Stanley Chetcuti
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Stanley Chetcuti were reported at $155,691. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Stanley Chetcuti | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $46,050 | $450 | $127–$1,392 | $163 |
| 2020 | $74,934 | $242 | $77–$751 | $114 |
| 2021 | $63,298 | $335 | $101–$1,037 | $132 |
| 2022 | $52,803 | $395 | $121–$1,211 | $149 |
| 2023 | $108,218 | $443 | $136–$1,283 | $160 |
| 2024 | $71,721 | $450 | $136–$1,323 | $164 |
| 2025 | $155,691 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
606
Drug cost
$47,158
Branded share of claims
28.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 28 | $36,429 | |
| Ranolazine Er Ranolazine | Brand | 15 | $2,161 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 99 | $1,752 | |
| Metoprolol Succinate | Generic | 72 | $1,422 | |
| Atorvastatin Calcium | Generic | 66 | $1,298 | |
| Rosuvastatin Calcium | Generic | 53 | $1,237 | |
| Ezetimibe | Generic | 20 | $737 | |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | Brand | 21 | $437 | |
| Lisinopril | Generic | 45 | $386 | |
| Amlodipine Besylate | Generic | 44 | $339 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$90,338
Medicare patients
258
Services billed
534
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Heart failure | 69% | |
| Atrial fibrillation | 54% | |
| Arthritis | 47% | |
| Chronic kidney disease | 46% | |
| Diabetes | 42% | |
| COPD | 29% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,503 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Michigan
Marschall Runge
Cardiovascular Disease · Ann Arbor, MI
Jihad Mustapha
Cardiovascular Disease · Grand Rapids, MI
Vallerie McLaughlin
Cardiovascular Disease · Ann Arbor, MI
Pedro Villablanca Spinetto
Cardiovascular Disease · Detroit, MI
David Haines
Cardiovascular Disease · Royal Oak, MI
Steven Almany
Cardiovascular Disease · Troy, MI
Related records
Cardiovascular Disease in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.